Spectranetics Gives Philips Adjacent Territory In Image-Guided Therapy

The plum in the middle of Philips' intense period of M&A this summer was the €1.9 billion purchase of Spectranetics, which, combined with Philips Volcano, should create a $1 billion+ devices business within the image-guided therapy group by 2020. IGT senior vice president and general manager Bert van Meurs explains the rationale behind the deal, and what's next for Philips.

Frans van Houten was taking a peek into the future two and a half years ago when Philips Healthcare brought Volcano Corp. into the fold. "An important milestone in our strategy to become the leading systems integrator in the fast-growing image-guided minimally invasive surgery market," is how the group CEO described the deal that was completed in February 2015.

In June 2017, he took another step toward that aim in agreeing to buy US vascular interventions and cardiac solutions company Spectranetics Corp. (Colorado Springs, CO) for €1.9 billion...

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By 

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By 

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.